BCMA CAR-T therapy achieves 100% MRD negativity in transplant-ineligible multiple myeloma patients
A One-Time Treatment Erases Early-Stage Blood Cancer in Older Adults
This Phase II, open-label, single-arm trial evaluated BCMA CAR-T infusion in 36 patients with newly diagnosed multiple myeloma ineligible fo…
A new approach using a patient’s own re-engineered immune cells is showing unprecedented success in wiping out a common blood cancer from th…
Early daratumumab or immunomodulatory agents in high-risk smoldering multiple myeloma show uncertain benefits versus observation
Early Drug May Delay Multiple Myeloma
This systematic review evaluated early intervention with monoclonal antibodies, immunomodulatory agents, or alkylating agents versus observa…
Imagine waking up with a headache. You take a pill, and the pain goes away.
Linvoseltamab shows improved outcomes versus real-world standard of care in relapsed/refractory multiple myeloma
New Hope for Myeloma Patients After Three Failed Treatments
A Phase 1/2 study with an external control arm compared linvoseltamab to real-world standard of care in 105 triple-class exposed or refracto…
Patients with multiple myeloma who failed three prior treatments show higher response rates and longer survival with linvoseltamab compared …
Anti-BCMA CAR T-cell therapy bb21217 with bb007 showed 69.4% response in relapsed multiple myeloma
Memory Cells Make CAR T Last Longer
This Phase I study evaluated anti-B-cell maturation antigen CAR T-cell therapy bb21217 manufactured with the phosphoinositide 3-kinase inhib…
CAR T cells trained to act like long-term guards may keep multiple myeloma away for years instead of burning out quickly after initial treat…
Carfilzomib-lenalidomide-dexamethasone improves progression-free survival versus lenalidomide after transplant in multiple myeloma
Adding carfilzomib to lenalidomide improved survival in multiple myeloma patients after stem cell transplant
In a phase 3 trial of 180 patients with newly diagnosed multiple myeloma after autologous HSCT, carfilzomib-lenalidomide-dexamethasone maint…
Adding carfilzomib to lenalidomide after stem cell transplant boosted four-year survival to 67.5% compared to 38.0% for patients on lenalido…
Multiple myeloma diagnosis associated with markedly increased hematologic second primary malignancies in 279,894 patients
Multiple myeloma patients show higher risk of second blood cancers, review finds
This systematic review and meta-analysis evaluated second primary malignancy risks in 279,894 patients with multiple myeloma compared to the…
Multiple myeloma patients face a threefold higher risk of developing a second blood cancer compared to the general population, according to …
Systematic review explores necroptosis as a therapeutic target in multiple myeloma
Could a different kind of cell death help treat stubborn blood cancer?
A systematic review integrates current evidence on necroptosis in multiple myeloma.
When standard treatments fail, triggering a different cell death process called necroptosis might kill resistant cancer cells and boost the …
CellSearch CMMC assay shows analytical sensitivity for non-invasive MRD monitoring in multiple myeloma
Could a simple blood test replace painful bone marrow biopsies for myeloma monitoring?
A study of unspecified design evaluated the analytical performance of the CellSearch CMMC assay for minimal residual disease monitoring in m…
A new blood test can detect single cancer cells left after multiple myeloma treatment, offering a less invasive way to monitor disease level…
Real-world study shows lenalidomide-dexamethasone yields 22.9-month PFS in transplant-ineligible myeloma
Real-world study shows lenalidomide treatment outcomes for older multiple myeloma patients
A prospective, non-interventional study of 168 transplant-ineligible NDMM patients in Germany found median PFS of 22.9 months and OS of 58.1…
Real-world data shows lenalidomide plus low-dose dexamethasone keeps older multiple myeloma patients disease-free for nearly two years while…
Review examines adoptive cellular therapies and immunoproteasome role in relapsed/refractory multiple myeloma
Review explores cellular therapies and immune system targeting for multiple myeloma
A systematic review discusses emerging evidence for adoptive cellular therapies (CAR T-cells, TCR-engineered T-cells) in relapsed/refractory…
Cellular therapies like CAR T-cells show promise for treating multiple myeloma, but severe side effects, high costs, and resistance limit th…
Bisphosphonates reduce vertebral fracture risk in multiple myeloma, spinal cord compression effect unclear
Can bone drugs protect the spine in multiple myeloma? A new review weighs in
A meta-analysis of 11 randomized trials in adults with multiple myeloma found bisphosphonates reduced vertebral fracture risk compared to no…
Bone drugs called bisphosphonates lower the risk of spine fractures in multiple myeloma patients, though evidence on preventing spinal cord …
Phase 1 trial of WVT078 with/without WHG626 shows preliminary activity in relapsed/refractory multiple myeloma
Can a new combination therapy help when multiple myeloma returns?
A phase 1 dose-escalation trial in 56 patients with relapsed/refractory multiple myeloma assessed the BCMA×CD3 bispecific antibody WVT078 al…
Adding a second drug to a new antibody therapy nearly doubled response rates in early trials for patients with returning multiple myeloma.